RAPP
Income statement / Annual
Last year (2024), Rapport Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Rapport Therapeutics, Inc. Common Stock's net income was -$78.31 M.
See Rapport Therapeutics, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$839.00 K
|
$112.00 K
|
$15.00 K
|
| Gross Profit |
-$839.00 K
|
-$112.00 K
|
-$15.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$60.94 M
|
$28.00 M
|
$9.12 M
|
| General & Administrative Expenses |
$22.12 M
|
$8.18 M
|
$1.37 M
|
| Selling & Marketing Expenses |
$0.00
|
-$112.00 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$22.12 M
|
$8.07 M
|
$1.37 M
|
| Other Expenses |
-$839.00 K
|
$0.00
|
-$128.82 K
|
| Operating Expenses |
$82.22 M
|
$36.07 M
|
$10.35 M
|
| Cost And Expenses |
$83.06 M
|
$36.18 M
|
$10.37 M
|
| Interest Income |
$12.14 M
|
$2.53 M
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$285.00 K
|
| Depreciation & Amortization |
$839.00 K
|
$112.00 K
|
$15.00 K
|
| EBITDA |
-$77.47 M |
-$34.66 M |
-$10.35 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.75 M
|
$1.40 M
|
-$285.00 K
|
| Income Before Tax |
-$78.31 M
|
-$34.78 M
|
-$10.65 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$10.00 K
|
$0.00
|
| Net Income |
-$78.31 M
|
-$34.79 M
|
-$10.65 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-0.38 |
-0.19 |
-0.053 |
| EPS Diluted |
-0.38 |
-0.19 |
-0.053 |
| Weighted Average Shares Out |
$207.38 M
|
$180.79 M
|
$201.17 M
|
| Weighted Average Shares Out Diluted |
$207.38 M
|
$180.79 M
|
$201.17 M
|
| Link |
|
|
|
